유방암 액체생검 시장 규모는 향후 수년간 급성장할 것으로 예측됩니다. 예측 기간의 성장 원동력은 액체생검 어세이의 기술적 진보, 조기 암 스크리닝에 액체생검 채용 증가, 실시간암 모니터링 수요 증가, 프레시전· 종양에의 응용 확대, 액체생검 연구개발에 대한 투자 확대입니다. 주요 동향으로서는 액체생검 해석에 있어서의 인공지능의 통합, 싱글 셀 시퀀싱의 진전, 멀티오믹스 액체생검 플랫폼의 개발, 액체생검의 감도와 특이도의 향상 등이 있습니다.
유방암 증례 증가는 향후 수년간 유방암 액체생검 시장의 성장을 가속할 것으로 예측됩니다. 유방암은 유방세포에서 발생하는 악성 종양이며, 일반적으로는 우유를 생산하는 작은 잎이나 우유를 젖꼭지로 운반하는 유관에 발생합니다. 유방암의 유병률 증가는 유전적 소인, 호르몬 균형의 혼란, 고령화, 라이프 스타일의 변화, 비만, 음주, 운동 부족, 방사선 피폭, 환경 오염 물질 등의 요인에 기인하고 있습니다. 유방암 액체생검은 혈액 중의 순환 종양 DNA(ctDNA) 또는 순환 종양 세포(CTC)를 검출하고 실시간으로 질병 모니터링을 가능하게 함으로써 치료에 중요한 역할을 하고 있습니다. 치료 효과의 평가, 치료 저항성의 검출, 표적 치료를 위한 유전자 변이의 동정에 도움이 됩니다. 예를 들어, 암 연구, 교육, 광고, 환자 지원을 목적으로 하는 미국의 비영리 단체인 미국암 협회에 따르면 유방암의 신규 환자수는 2024년 31만 3,510명에서 2025년 31만 9,750명으로 증가할 것으로 예측되고 있습니다. 그 결과, 유방암 이환율 증가가 유방암 액체생검 시장의 확대에 박차를 가하고 있습니다.
유방암 액체생검 시장의 주요 기업은 동반진단약 등 혁신적인 시장 개척에 주력하고 있으며, 특정 치료법이 가장 유효한 환자를 특정함으로써 맞춤형 치료를 촉진하고 있습니다. 동반 진단은 액체생검 기술을 활용하여 유전자 돌연변이, 순환 종양 DNA(ctDNA), 치료 반응성을 나타내는 단백질 발현을 포함한 바이오마커를 검출합니다. 예를 들어, 2023년 1월 미국 소재 생명공학 회사인 Guardant Health는 ESR1 변이가 있는 진행성 또는 전이성 유방암 환자를 위한 치료제인 메나리니 그룹의 오르세르듀(엘라세스트란트)의 동반 진단으로 Guardant360 CDx 액체생검 검사에 대한 식품의약국(FDA)의 승인을 받았습니다. 이번 승인으로 종양 전문의는 이 검사를 사용하여 포괄적인 게놈 프로파일링을 수행하여 표적 치료의 혜택을 받을 수 있는 환자를 식별할 수 있게 되었습니다. 또한 가던트 헬스의 유방암에 대한 첫 번째 FDA 승인으로 정밀 종양학 분야에서 입지를 강화할 수 있게 되었습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계의 유방암 액체생검 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
- 최종 이용 산업의 분석
- 세계의 유방암 액체생검 시장 : 성장률 분석
- 세계의 유방암 액체생검 시장 실적 : 규모와 성장(2019-2024년)
- 세계의 유방암 액체생검 시장 예측 : 규모와 성장(2024-2029년, 2034년)
- 세계의 유방암 액체생검 전체 시장(TAM)
제6장 시장 세분화
- 세계의 유방암 액체생검 시장 : 제품별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 소모품
- 키트
- 세계의 유방암 액체생검 시장 : 바이오마커별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 세포 외 소포(EV)
- 무세포 DNA(cfDNA)
- 순환 종양 RNA(ctRNA)
- 순환 종양 세포(CTC)
- 무세포 RNA(cfRNA)
- 기타 바이오마커
- 세계의 유방암 액체생검 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 조기 발견 또는 검진
- 진단
- 기타 용도
- 세계의 유방암 액체생검 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 연구소
- 병원
- 의사 연구실
- 참고 연구실
- 공중보건연구실
- 연구기관
- 소분자 연구실
- 병리 연구실
- 세계의 유방암 액체생검 시장 : 소모품 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 시약
- 중합효소 연쇄반응(PCR) 분석
- 시퀀싱 패널
- 샘플 수집 튜브
- 세계의 유방암 액체생검 시장 : 키트 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- DNA 기반 액체생검 키트
- RNA 기반 액체생검 키트
- 멀티 마커 액체생검 키트
제7장 지역별/국가별 분석
- 세계의 유방암 액체생검 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 유방암 액체생검 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
- 유방암 액체생검 시장 : 경쟁 구도
- 유방암 액체생검 시장 : 기업 프로파일
- Johnson & Johnson Private Limited 개요, 제품 및 서비스, 전략 및 재무 분석
- Roche Diagnostics 개요, 제품 및 서비스, 전략 및 재무 분석
- Merck KGaA 개요, 제품 및 서비스, 전략 및 재무 분석
- Thermo Fisher Scientific 개요, 제품 및 서비스, 전략 및 재무 분석
- Siemens Healthineers 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- Agilent Technologies Inc.
- Illumina Inc.
- Sysmex Corporation
- Qiagen NV
- Myriad Genetics Inc.
- NeoGenomics Laboratories
- Guardant Health Inc.
- Twist Bioscience
- Foundation Medicine Inc.
- Biodesix Inc.
- Menarini Silicon Biosystems
- Datar Cancer Genetics
- Abcam plc
- OncoDNA SA
- Genomic Health Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- 유방암 액체생검 시장(2029년) : 새로운 기회를 제공하는 국가
- 유방암 액체생검 시장(2029년) : 새로운 기회를 제공하는 부문
- 유방암 액체생검 시장(2029년) : 성장 전략
제36장 부록
KTH
A breast cancer liquid biopsy is a minimally invasive test that detects and analyzes tumor-derived materials in a patient's blood or other bodily fluids, offering valuable insights into the presence, progression, and genetic profile of breast cancer without the need for a traditional tissue biopsy.
The primary products used in breast cancer liquid biopsy include consumables and kits. Consumables refer to disposable materials, reagents, and kits utilized in liquid biopsy tests to detect and analyze biomarkers associated with breast cancer. The key biomarkers include extracellular vesicles (EVs), cell-free DNA (cfDNA), circulating tumor RNA (ctRNA), circulating tumor cells (CTCs), cell-free RNA (cfRNA), and others. These biomarkers are applied in early detection or screening, diagnosis, and other purposes. The end users of breast cancer liquid biopsy encompass laboratories, hospitals, physician laboratories, reference laboratories, public health laboratories, research institutes, small molecular laboratories, and pathology laboratories.
The breast cancer liquid biopsy market research report is one of a series of new reports from The Business Research Company that provides breast cancer liquid biopsy market statistics, including breast cancer liquid biopsy industry global market size, regional shares, competitors with a breast cancer liquid biopsy market share, detailed breast cancer liquid biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer liquid biopsy industry. This breast cancer liquid biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The breast cancer liquid biopsy market size has grown rapidly in recent years. It will grow from $0.78 billion in 2024 to $0.90 billion in 2025 at a compound annual growth rate (CAGR) of 15.0%. The growth during the historic period can be attributed to advancements in next-generation sequencing (NGS), the increasing prevalence of breast cancer, the growing demand for non-invasive diagnostic methods, the rising adoption of personalized medicine, and increased funding for cancer research.
The breast cancer liquid biopsy market size is expected to see rapid growth in the next few years. It will grow to $1.56 billion in 2029 at a compound annual growth rate (CAGR) of 14.7%. The projected growth in the forecast period is driven by technological advancements in liquid biopsy assays, increasing adoption of liquid biopsy for early cancer screening, rising demand for real-time cancer monitoring, expanding applications in precision oncology, and growing investments in liquid biopsy research and development. Key trends include the integration of artificial intelligence in liquid biopsy analysis, advancements in single-cell sequencing, the development of multi-omics liquid biopsy platforms, improvements in liquid biopsy sensitivity and specificity, and the adoption of digital PCR for ultra-precise mutation detection.
The rising number of breast cancer cases is expected to drive the growth of the breast cancer liquid biopsy market in the coming years. Breast cancer is a malignancy that originates in the breast cells, typically in the milk-producing lobules or the ducts that transport milk to the nipple. The increasing prevalence of breast cancer is attributed to factors such as genetic predisposition, hormonal imbalances, an aging population, lifestyle changes, obesity, alcohol consumption, physical inactivity, radiation exposure, and environmental pollutants. Breast cancer liquid biopsy plays a crucial role in treatment by detecting circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the blood, enabling real-time disease monitoring. It helps assess treatment response, detect therapy resistance, and identify genetic mutations for targeted therapies. For example, according to the American Cancer Society, a US-based nonprofit organization dedicated to cancer research, education, advocacy, and patient support, new breast cancer cases are projected to increase from 313,510 in 2024 to 319,750 in 2025. As a result, the growing incidence of breast cancer is fueling the expansion of the breast cancer liquid biopsy market.
Leading companies in the breast cancer liquid biopsy market are focusing on innovative developments, such as companion diagnostics, to facilitate personalized treatment by identifying patients who are most likely to benefit from specific therapies. Companion diagnostics leverage liquid biopsy technology to detect biomarkers, including genetic mutations, circulating tumor DNA (ctDNA), and protein expressions that indicate treatment responsiveness. For instance, in January 2023, Guardant Health Inc., a US-based biotechnology company, received Food and Drug Administration (FDA) approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for Menarini Group's ORSERDU (elacestrant), a therapy for advanced or metastatic breast cancer patients with ESR1 mutations. This approval allows oncologists to conduct comprehensive genomic profiling using the test, enabling them to identify patients who may benefit from targeted therapy. It also marks Guardant Health's first FDA approval for breast cancer, strengthening its presence in precision oncology.
In January 2024, Guardant Health Inc. partnered with Hikma Pharmaceuticals plc to enhance early cancer detection, monitor recurrence, and optimize treatment selection using Guardant Health's advanced liquid and tissue biopsy technologies. This collaboration strengthens Guardant Health's global presence and addresses the increasing cancer burden in the Middle East and North Africa. Hikma Pharmaceuticals plc is a UK-based pharmaceutical company specializing in innovative healthcare solutions.
Major players in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc.
North America was the largest region in the breast cancer liquid biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in breast cancer liquid biopsy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the breast cancer liquid biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The breast cancer liquid biopsy market consists of revenues earned by entities by providing services such as early cancer detection, treatment monitoring, minimal residual disease (MRD) detection, recurrence prediction, and genetic mutation analysis for targeted therapy selection. The market value includes the value of related goods sold by the service provider or included within the service offering. The breast cancer liquid biopsy market also includes sales of circulating tumor DNA (ctDNA) assay kits, circulating tumor cell (CTC) detection systems, next-generation sequencing (NGS) panels, PCR-based liquid biopsy tests, blood collection tubes, and consumables and reagents used for non-invasive cancer diagnostics and monitoring. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Breast Cancer Liquid Biopsy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on breast cancer liquid biopsy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for breast cancer liquid biopsy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The breast cancer liquid biopsy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Product: Consumables; Kits
- 2) By Biomarkers: Extracellular Vesicles (EVs); Cell-free DNA (cfDNA); Circulating Tumor RNA (ctRNA); Circulating Tumor Cells (CTCs); Cell-free RNA (cfRNA); Other Biomarkers
- 3) By Application: Early Detection Or Screening; Diagnosis; Other Applications
- 4) By End Users: Laboratories; Hospitals; Physician Laboratories; Reference Laboratories; Public Health Laboratories; Research Institutes; Small Molecular Laboratories; Pathology Laboratories
- Subsegments:
- 1) By Consumables: Reagents; Polymerase Chain Reaction (PCR) Assays; Sequencing Panels; Sample Collection Tubes
- 2) By Kits: DNA-based Liquid Biopsy Kits; RNA-based Liquid Biopsy Kits; Multi-marker Liquid Biopsy Kits
- Companies Mentioned: Johnson & Johnson Private Limited; Roche Diagnostics; Merck KGaA; Thermo Fisher Scientific; Siemens Healthineers
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Breast Cancer Liquid Biopsy Market Characteristics
3. Breast Cancer Liquid Biopsy Market Trends And Strategies
4. Breast Cancer Liquid Biopsy Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Breast Cancer Liquid Biopsy Growth Analysis And Strategic Analysis Framework
- 5.1. Global Breast Cancer Liquid Biopsy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Breast Cancer Liquid Biopsy Market Growth Rate Analysis
- 5.4. Global Breast Cancer Liquid Biopsy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Breast Cancer Liquid Biopsy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Breast Cancer Liquid Biopsy Total Addressable Market (TAM)
6. Breast Cancer Liquid Biopsy Market Segmentation
- 6.1. Global Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Consumables
- Kits
- 6.2. Global Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Extracellular Vesicles (EVs)
- Cell-free DNA (cfDNA)
- Circulating Tumor RNA (ctRNA)
- Circulating Tumor Cells (CTCs)
- Cell-free RNA (cfRNA)
- Other Biomarkers
- 6.3. Global Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Early Detection Or Screening
- Diagnosis
- Other Applications
- 6.4. Global Breast Cancer Liquid Biopsy Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Laboratories
- Hospitals
- Physician Laboratories
- Reference Laboratories
- Public Health Laboratories
- Research Institutes
- Small Molecular Laboratories
- Pathology Laboratories
- 6.5. Global Breast Cancer Liquid Biopsy Market, Sub-Segmentation Of Consumables, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Reagents
- Polymerase Chain Reaction (PCR) Assays
- Sequencing Panels
- Sample Collection Tubes
- 6.6. Global Breast Cancer Liquid Biopsy Market, Sub-Segmentation Of Kits, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- DNA-based Liquid Biopsy Kits
- RNA-based Liquid Biopsy Kits
- Multi-marker Liquid Biopsy Kits
7. Breast Cancer Liquid Biopsy Market Regional And Country Analysis
- 7.1. Global Breast Cancer Liquid Biopsy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Breast Cancer Liquid Biopsy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Breast Cancer Liquid Biopsy Market
- 8.1. Asia-Pacific Breast Cancer Liquid Biopsy Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Breast Cancer Liquid Biopsy Market
- 9.1. China Breast Cancer Liquid Biopsy Market Overview
- 9.2. China Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Breast Cancer Liquid Biopsy Market
- 10.1. India Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Breast Cancer Liquid Biopsy Market
- 11.1. Japan Breast Cancer Liquid Biopsy Market Overview
- 11.2. Japan Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Breast Cancer Liquid Biopsy Market
- 12.1. Australia Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Breast Cancer Liquid Biopsy Market
- 13.1. Indonesia Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Breast Cancer Liquid Biopsy Market
- 14.1. South Korea Breast Cancer Liquid Biopsy Market Overview
- 14.2. South Korea Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Breast Cancer Liquid Biopsy Market
- 15.1. Western Europe Breast Cancer Liquid Biopsy Market Overview
- 15.2. Western Europe Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Breast Cancer Liquid Biopsy Market
- 16.1. UK Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Breast Cancer Liquid Biopsy Market
- 17.1. Germany Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Breast Cancer Liquid Biopsy Market
- 18.1. France Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Breast Cancer Liquid Biopsy Market
- 19.1. Italy Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Breast Cancer Liquid Biopsy Market
- 20.1. Spain Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Breast Cancer Liquid Biopsy Market
- 21.1. Eastern Europe Breast Cancer Liquid Biopsy Market Overview
- 21.2. Eastern Europe Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Breast Cancer Liquid Biopsy Market
- 22.1. Russia Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Breast Cancer Liquid Biopsy Market
- 23.1. North America Breast Cancer Liquid Biopsy Market Overview
- 23.2. North America Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Breast Cancer Liquid Biopsy Market
- 24.1. USA Breast Cancer Liquid Biopsy Market Overview
- 24.2. USA Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Breast Cancer Liquid Biopsy Market
- 25.1. Canada Breast Cancer Liquid Biopsy Market Overview
- 25.2. Canada Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Breast Cancer Liquid Biopsy Market
- 26.1. South America Breast Cancer Liquid Biopsy Market Overview
- 26.2. South America Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Breast Cancer Liquid Biopsy Market
- 27.1. Brazil Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Breast Cancer Liquid Biopsy Market
- 28.1. Middle East Breast Cancer Liquid Biopsy Market Overview
- 28.2. Middle East Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Breast Cancer Liquid Biopsy Market
- 29.1. Africa Breast Cancer Liquid Biopsy Market Overview
- 29.2. Africa Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Breast Cancer Liquid Biopsy Market Competitive Landscape And Company Profiles
- 30.1. Breast Cancer Liquid Biopsy Market Competitive Landscape
- 30.2. Breast Cancer Liquid Biopsy Market Company Profiles
- 30.2.1. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Roche Diagnostics Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Siemens Healthineers Overview, Products and Services, Strategy and Financial Analysis
31. Breast Cancer Liquid Biopsy Market Other Major And Innovative Companies
- 31.1. Agilent Technologies Inc.
- 31.2. Illumina Inc.
- 31.3. Sysmex Corporation
- 31.4. Qiagen N.V.
- 31.5. Myriad Genetics Inc.
- 31.6. NeoGenomics Laboratories
- 31.7. Guardant Health Inc.
- 31.8. Twist Bioscience
- 31.9. Foundation Medicine Inc.
- 31.10. Biodesix Inc.
- 31.11. Menarini Silicon Biosystems
- 31.12. Datar Cancer Genetics
- 31.13. Abcam plc
- 31.14. OncoDNA SA
- 31.15. Genomic Health Inc.
32. Global Breast Cancer Liquid Biopsy Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Breast Cancer Liquid Biopsy Market
34. Recent Developments In The Breast Cancer Liquid Biopsy Market
35. Breast Cancer Liquid Biopsy Market High Potential Countries, Segments and Strategies
- 35.1 Breast Cancer Liquid Biopsy Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Breast Cancer Liquid Biopsy Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Breast Cancer Liquid Biopsy Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
